Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy of Eslicarbazepine Acetate as First Adjunctive Therapy with Levetiracetam or Lamotrigine, or as Later Adjunctive Therapy in Patients with Focal Seizures
Epilepsy/Clinical Neurophysiology (EEG)
P9 - Poster Session 9 (12:00 PM-1:00 PM)
12-002

To evaluate efficacy of eslicarbazepine acetate (ESL) as a first adjunctive therapy with levetiracetam (LEV) or lamotrigine (LTG) monotherapy, or as later adjunctive therapy in treatment-resistant patients with focal seizures; safety and tolerability data are reported by Cantu et al.
ESL is a once-daily, oral antiepileptic drug (AED) that has been shown to be effective and well tolerated for focal seizures in a number of clinical trials, including as adjunctive therapy in treatment-resistant patients.
A multicenter, open-label, non-randomized study of adjunctive ESL in patients aged ≥18 years with focal seizures (NCT03116828). Arm 1: ESL as first adjunctive therapy with LEV (n=28) or LTG (n=14). Arm 2: ESL as a later adjunctive therapy, following prior use of 1–2 AEDs (n=59). The trial comprised screening (1–2 weeks), titration (2 weeks), maintenance (24 weeks), and ESL taper/safety follow-up (4 weeks) periods.
Overall, 102 patients entered the study (Arm 1: n=43; Arm 2: n=59); 69.8% of patients in Arm 1 and 55.9% of patients in Arm 2 completed the 24-week maintenance period. At 24 weeks, median reductions in standardized seizure frequency (SSF) were higher in Arm 1 (74.0%) than in Arm 2 (23.7%). Responder rates (proportion of patients with ≥50% reduction in SSF) were also higher in Arm 1 (63.2%) than in Arm 2 (37.7%). In Arm 1, 26.3% of patients remained seizure free during the 24-week maintenance period, compared with 9.4% of patients in Arm 2.

This study demonstrated for the first time that ESL was effective as a first adjunctive therapy with LEV or LTG, and confirmed that ESL was effective as a later adjunctive therapy in treatment-resistant patients with focal seizures. Seizure improvements were greater when ESL was taken as a first adjunctive therapy with LEV or LTG monotherapy, compared with when taken as a later adjunctive therapy.

Authors/Disclosures
Andrei Pikalov
PRESENTER 		No disclosure on file
Todd Grinnell, PhD Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
John D. Hixson, MD (Neurona Therapeutics) Dr. Hixson has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Hixson has received personal compensation for serving as an employee of Nile Ai. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NextSense Inc.. Dr. Hixson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seer Medical. Dr. Hixson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Expert Institute. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Reviewer with Epilepsy Study Consortium.
No disclosure on file
No disclosure on file
David Cantu, PhD (Xenon Pharmaceuticals Inc) Dr. Cantu has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..